Prusogliptin

普卢格列汀

Report date: 2025/01/13 15:31:31
NME

Base Information

Drug NamePrusogliptin
Drug Alias Name善泽平DBPR-108
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2Renal InsufficiencyHepatic Insufficiency
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/08
Country/TerritoryTaiwanMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTaiwan Shenlong Co LtdNational Health Research Institutes
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCspc Ouyi Pharmaceutical Co Ltd
Inactive CompaniesNational Health Research InstitutesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Active IndicationsDiabetes Mellitus, Type 2Renal InsufficiencyHepatic Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A